ClinicalTrials.gg
RecruitingNCT06953999Updated Mar 4, 2026

A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer

A Phase 3 interventional study of Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine and Ivonescimab, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine in Pancreatic Cancer, sponsored by Akeso. Recruiting at 3 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Akeso · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
999
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 630 studies in Pancreatic Neoplasms with a site in China — 334 open to participants now, 359 under way, 30 of them phase 3. Pancreatic Neoplasms · China.

Planned enrollment
6th of 508
999 · median 58
Started
2025
with 83 others
Phase 3
41 of 630
22 open now
Primary completion
2027-05
later than 232 of 358 live
Registered
508th of 630
by date

Among the 630 studies in Pancreatic Neoplasms with a site in China, this one is the 6th largest by planned enrollment of the 508 interventional ones that give a count, is one of 84 that started in 2025, is one of 41 in phase 3, reaches primary completion later than 232 of the 358 other live ones, and was the 508th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

334 of the 630 studies in Pancreatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

329 more — sign in →

All 334 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 630 studies in Pancreatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a Phase 3, randomized, double-blind clinical trial aimed at evaluating the efficacy and safety of Ivonescimab plus chemotherapy with or without AK117 versus placebo plus chemotherapy in patients with metastatic pancreatic cancer. The study seeks to determine whether the addition of Ivonescimab and/or AK117 improves clinical outcomes compared to standard chemotherapy alone. Participants will be randomly assigned to receive either Ivonescimab with/without AK117 or placebo, both in combination with chemotherapy.

03

Conditions studied

  • Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign a written form.
  2. Age at enrollment is ≥ 18 and ≤ 75 years, both males and females are eligible.
  3. (ECOG) performance status of 0 or 1.
  4. of ≥ 3 months.
  5. or cytologically confirmed, unresectable pancreatic ductal adenocarcinoma (PDAC).
  6. No prior systemic anti-cancer treatment for metastatic PDAC.
  7. At least one per (RECIST) v1.1.
  8. Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  1. or cytologically confirmed other types of pancreatic or mixed histology types.
  2. Presence of active central nerve system (CNS) .
  3. Known germline BRCA1/2 or PALB2 mutations.
  4. or recurrent pleural effusion, pericardial effusion, or ascites requiring drainage.
  5. History of other malignancies within the past 5 years.
  6. History of significant bleeding tendencies or coagulopathy; clinically significant bleeding events within 1 month before the first dose.
  7. Previous anti-angiogenic therapy and immunotherapy.
  8. Active disease requiring systemic treatment within the past 2 years.
  9. Pregnant or breastfeeding women.
  10. Concurrent participation in another clinical trial, unless it is an observational or non-interventional study or in the follow-up phase of an interventional study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
999 participants (estimated)

Study arms

  • Experimental
    Ivonescimab + AK117 + Albumin-bound Paclitaxel + Gemcitabine

    Drug: Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine

  • Experimental
    Ivonescimab + AK117 Placebo + Albumin-bound Paclitaxel + Gemcitabine

    Drug: Ivonescimab, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine

  • Active comparator
    Ivonescimab Placebo + AK117 Placebo + Albumin-bound Paclitaxel + Gemcitabine

    Drug: Ivonescimab Placebo, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine

Interventions

  • DrugIvonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine

    Drug pages: Ivonescimab · Ligufalimab · Albumin-Bound Paclitaxel · Gemcitabine

    Ivonescimab: a specified dose and frequency administrated by intravenous infusion (IV). AK117: a specified dose and frequency administrated by intravenous infusion (IV). Albumin-bound Paclitaxel: 125 mg/m2 weekly for 3 weeks followed by 1 week of rest. Gemcitabine: 1000 mg/m2 weekly for 3 weeks followed by 1 week of rest.

  • DrugIvonescimab, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine

    Ivonescimab: a specified dose and frequency administrated by intravenous infusion (IV). AK117 Placebo: a specified dose and frequency administrated by intravenous infusion (IV). Albumin-bound Paclitaxel: 125 mg/m2 weekly for 3 weeks followed by 1 week of rest. Gemcitabine: 1000 mg/m2 weekly for 3 weeks followed by 1 week of rest.

  • DrugIvonescimab Placebo, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine

    Ivonescimab Placebo : a specified dose and frequency administrated by intravenous infusion (IV). AK117 Placebo : a specified dose and frequency administrated by intravenous infusion (IV). Albumin-bound Paclitaxel: 125 mg/m2 weekly for 3 weeks followed by 1 week of rest. Gemcitabine: 1000 mg/m2 weekly for 3 weeks followed by 1 week of rest.

06

What researchers measure

Primary outcomes

  1. Overall response (OS)

    Overall Survival (OS) is defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Progression Free Survival (PFS) assessed by investigator per RECIST v1.1

    PFS is defined as the time from randomization to the first documented disease progression (per RECIST v1.1 criteria) assessed by investigators or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 2 years

  2. Objective Response Rate (ORR) assessed by investigator per RECIST v1.1

    ORR is the proportion of subjects with complete response(CR) or partial response(PR) , assessed by investigators based on RECIST v1.1.

    Time frame: Up to approximately 2 years

  3. Disease Control Rate (DCR) assessed by investigator per RECIST v1.1

    Disease control rate (DCR) assessed according to RECIST v1.1.

    Time frame: Up to approximately 2 years

  4. Duration of response (DoR) assessed by the investigator per RECIST v1.1

    Duration of response (DoR) assessed according to RECIST v1.1.

    Time frame: Up to approximately 2 years

  5. Time to response (TTR) assessed by the investigator per RECIST v1.1

    Time to response (TTR) is defined as the time to response based on RECIST v1.1.

    Time frame: Up to approximately 2 years

  6. Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant, temporarily associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: Up to approximately 2 years

  7. Cmax and Cmin

    AK112 serum drug concentrations in subjects at different time points after AK112 administration.

    Time frame: Up to approximately 2 years

  8. Anti-drug antibodies (ADA)

    Number of subjects with detectable anti-drug antibodies (ADA).

    Time frame: Up to approximately 2 years

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for May 2027, 23 months after the start.

Of 84 phase 3 interventional studies under Pancreatic Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 77. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2025
First posted
May 1, 2025
StartActual
Jun 11, 2025
Primary completionEst.
May 14, 2027
CompletionEst.
May 14, 2028
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06953999
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
May 1, 2025
Start date
Jun 11, 2025
Primary completion
May 14, 2027 (estimated)
Completion
May 14, 2028 (estimated)
Last update
Mar 4, 2026

Study contacts

Wenting Li
Contact
wenting01.li@akesobio.com
+86-18116403289

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ivonescimab · Ligufalimab · Albumin-Bound Paclitaxel · Gemcitabine

Start the discussion